Dry Eye Crossover Study Could Allow Aldeyra A Quick Response To US FDA’s CRL For Reproxalap

 
• By Joseph Haas
  
Dry eye disease
Aldeyra hopes it can quickly refile its NDA for dry eye disease • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Complete Response Letters

More from Product Reviews